期刊文献+

嵌合抗原受体修饰的NK-92MI细胞对HER2阳性乳腺癌细胞的杀伤 被引量:3

Killing effect of NK-92MI cells modified with chimeric antigen receptor on HER2^+ breast carcinoma cell
下载PDF
导出
摘要 目的:探讨用特异性靶向HER2抗原的嵌合抗原受体(HER2-CAR)修饰的NK-92MI细胞对HER2阳性乳腺癌细胞的杀伤效率。方法:通过PCR获得HER2-CAR片段,运用常规分子克隆技术,将其构建到慢病毒载体上,利用包装的慢病毒颗粒对NK-92MI细胞进行转染;应用流式细胞术检测细胞转染效率以及转染前后NK-92MI的IFN-γ和颗粒酶分泌差异;使用7-AAD和流式细胞术体外检测HER2-CAR-NK92MI细胞对乳腺癌细胞的杀伤效率;构建小鼠乳腺癌原位肿瘤模型进行体内细胞毒性的检测。结果:用HER2-CAR修饰的NK-92MI细胞对HER2阳性乳腺癌肿瘤细胞MCF-7和T47D的杀伤效率明显高于未被基因修饰的NK-92MI细胞[分别为(62.4±1.3)%vs(22.1±1.2)%和(50.0±1.9)%vs(16.9±0.6)%,P<0.01];而两者对HER2阴性的乳腺癌细胞MDA-MB-468的杀伤效率没有明显差异[(13.6±1.4)%vs(12.7±0.8)%,P>0.05]。同时,经HER2-CAR修饰的NK-92MI细胞相比未被基因修饰的NK-92MI细胞,IFN-γ的分泌明显升高(P<0.01)。结论:经HER2-CAR修饰的NK-92MI细胞对HER2阳性乳腺癌细胞的杀伤效率明显提高,且具有特异性靶向,此为治疗乳腺癌等恶性肿瘤提供了临床依据。 Objective:To explore killing efficiency of NK-92MI cells modified with chimeric antigen receptor of specific targeting HER2 antigen (HER2-CAR) on HER2+ breast carcinoma cells. Methods: HER2-CAR fragments were obtained by PCR, then built into lentiviral vectors via molecular cloning technology and transfected into NK-92MI cells using the lentiviral particles with HER2-CAR. Flow cytometry assay was used to detect efficiency of the cell transfection and, secretion differences between IFN-γ and granzyme in NK-92MI cells before and after the transfection. Killing efficiency of HER2-CAR-NK92MI cells on breast carcinoma cells in vitro was tested with 7-AAD and flow cytometry assays. Mouse model with breast tumor in situ was constructed and used to detect killing efficiency of the HER2-CAR-NK92MI cells in vivo. Results:Killing efficiencies of the NK-92MI cell modified with HER2-CAR on HER2+ breast carcinoma MCF-7 and T47T cell lines were significantly higher than those of the NK-92MI cell that did not modified with HER2-CAR gene ([62.4±1.3]% vs[22.1±1.2/]%. [50.0±1.9]% vs [16.9±0.6]%, respectively, all P〈0.01). However, there was no obvious difference in killing efficiency of both the modified and un-modified NK-92MI cells on HER2- breast carcinoma MDA-MB-468 cell ([13.6±1.4]% vs [12.7±0.8]%,P〉0.05). At the same time, amount of IFN-γ secreted by the NK-92MI cell modified with HER2-CAR was significantly higher than that secreted by the NK-92MI cell which did not modified with HER2-CAR gene (P〈0.01).Conclusion: Killing efficiency of the NK-92MI cell modified with HER2-CAR on HER2+ breast carcinoma cell significantly increased, and could have specific targeting property, which might provide a clinical evidence for the treatment of malignant tumor, such as breast carcinoma and so on.
作者 孔潇 秦扬 李甲璐 游凤涛 朱学军 袁磊 孟会敏 安钢力 杨林 KONG Xiao QIN Yang LI Jialu YOU Fengtao ZHU Xuejun YUAN Lei MENG Huimin AN Gangli YANG Lin(The Cyrus Tang Hematology Center & Collaborative Innovation Center of Hematology, Soochow University, Suzhou215123, Jiangsu, China Departmentof Urology, Cancer Hospital of Yunan Province, Kunming 650118, Yun- nan, China Suzhou Cancer Immunotherapy-Diagnosis and Nanomedicine Engineering Technology Center, Suzhou 215123, Jiangsu, China PersonGen Biomedicine (Suzhou) Co. , Ltd, Suzhou 215123, Jiangsu, China Depart- ment of Hematology, Traditional Chinese Medicine Hospital of Jiangsu Province, Nanjing 210029, Jiangsu, China Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China)
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2016年第5期620-625,共6页 Chinese Journal of Cancer Biotherapy
基金 国家自然科学基金资助项目(No.31471283)~~
关键词 乳腺癌细胞 NK-92MI细胞 HER2嵌合抗原受体(HER2-CAR) breast carcinoma cell NK-92MI cell HER2 chimeric antigen receptor
  • 相关文献

参考文献18

  • 1SLAMON D J,CLARK G M,WONG S G,et al.Human breast cancer:correlation of relapse and survival with amplification of the HER2-2/neu oncogene[J].Science,1987,235(4785):177-182.
  • 2HOU J,ZHOU Z,CHEN X,et al.HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo[J/OL].Oncotarget,2016,2016 (Epub ahead of print)[2016-06-08].http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget.
  • 3GHAZALI N,PARKER L,SETTLE K,et al.Sustained response of HER2-positive metastatic salivary adenocarcinoma,not otherwise specified,treated with trastuzumab[J].Oral Surg Oral Med Oral Pathol Oral Radiol,2016,122(3):292-299.
  • 4VOGEL C L,COBLEIGH M A,TRIPATHY D,et al.Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer[J].J Clin Oncol,2002,20(3):719-726.
  • 5SUN L,BURNETT J,GASPARYAN M,et al.Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer[J/OL].Oncotarget,2016,2016(Epub ahead of print)[2016-06-08].http://www.impactjournals.com/oncotarget/.
  • 6KALOS M,LEVINE B L,PORTER D L,et al.T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia[J/OL].Sci Transl Med ,2011,3:95ra73[2016-06-08].http://stm.sciencemag.org/content/3/95/95ra73.long.
  • 7BRENTJENS R J,DAVILA M L,RIVIERE I,et al.CD19-targeted T cells rapidly induce molecular remissions in adults with chemotHERapyrefractory acute lymphoblastic leukemia[J].Sci Transl Med,2013,5(177):177ra38.
  • 8DAVILA M L,SADELAIN M.Biology and clinical application of CAR T cells for B cell malignancies[J].Int J Hematol,2016,104(1):6-17.
  • 9COLLIGNON J,LOUSBERG L,SCHROEDER H,et al.Triple-negative breast cancer:treatment challenges and solutions[J/OL].Breast Cancer (Dove Med Press),2016,8:93-107[2016-06-08].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881925/.
  • 10BHOJ V G,ARHONTOULIS D,WERTHEIM G,et al.Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T cell therapy[J].Blood,2016,128(3):360-370.

同被引文献7

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部